Abstract
The frequency of five-year survival in clinical stage III NSCLC (non-small cell lung cancer) is about 15-20%. Clinical stage III NSCLC is potentially curable.
In case of inoperability, chemoradiotherapy is the standard of treatment. Immunotherapy can significantly prolong the overall survival and improve quality of life.
Efficacy of durvalumab was demonstrated in an international phase III PACIFIC study (NCT02125461). Durvalumab is indicated as monotherapy for the treatment of adult patients with locally advanced, inoperable NSCLC with PD-L1 expression >= 1%, who showed no progression after platinum-based chemoradiotherapy.
In the Czech Republic, it is still necessary to apply for a payment permit according to § 16. Our case report describes the case of a 72-year-old woman, who was the first person in our country to be approved for treatment with durvalumab according to the paragraph above.